Evidence map›Paper›PMID 34331598›Full record

ArticleMedical oncology (Northwood, London, England)2021

Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.

Richard C Zieren, Liang Dong, David J Clark, Morgan D Kuczler, Kengo Horie, Leandro Ferreira Moreno, Tung-Shing M Lih, Michael Schnaubelt, Louis Vermeulen, Hui Zhang and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Biological Features of Extracellular Vesicles and Challenges.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Richard C Zieren *The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. rzieren1@jhmi.edu.
Liang Dong *The Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
David J Clark *Department of Pathology, The Johns Hopkins University, Baltimore, MD, 21287, USA.
Morgan D KuczlerThe Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Kengo HorieThe Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Leandro Ferreira MorenoOncode Institute, Amsterdam UMC, Amsterdam, The Netherlands.
Tung-Shing M LihDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, 21287, USA.
Michael SchnaubeltDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, 21287, USA.
Louis VermeulenOncode Institute, Amsterdam UMC, Amsterdam, The Netherlands.
Hui ZhangDepartment of Pathology, The Johns Hopkins University, Baltimore, MD, 21287, USA.
Theo M de ReijkeDepartment of Urology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Kenneth J PientaThe Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Sarah R AmendThe Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA. samend2@jhimi.edu.ORCID http://orcid.org/0000-0002-5606-1262
Johns Hopkins University · USOncode Institute · NLAmsterdam University Medical Centers · NL

Funding

Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KELLER, EVAN T · 2004 to 2024
$29.6M
TRANS_NETWORK PROJECTSU54CA143803 · NCI · PRINCETON UNIVERSITY · PI AUSTIN, ROBERT H. · 2009 to 2013
$14.2M
Glycoprotein biomarkers for the early detection of aggressive prostate cancerU01CA152813 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHANG, HUI · 2010 to 2021
$6.2M
The Comprehensive Proteome Characterization Center at Johns Hopkins: High Precision Discovery and Confirmation of Genoproteomic TargetsU24CA210985 · NCI · JOHNS HOPKINS UNIVERSITY · PI CHAN, DANIEL WANYUI, ZHANG, HUI · 2016 to 2020
$5.3M
Mechanisms That Regulate Dormancy of Disseminated Tumor Cells in the Bone MarrowU54CA163124 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHIOZAWA, YUSUKE · 2011 to 2015
$3.0M
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer ProgressionU01CA143055 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J., ROWLEY, DAVID R · 2010 to 2014
$2.7M
DOD Prostate Cancer Research Program W81XWH-20-10353Japan Society for the Promotion of Science KAKENHI: 19K18555NCI NIH HHS P01 CA093900NCI NIH HHS U01 CA143055NCI NIH HHS U01 CA152813NCI NIH HHS U01CA152813, U24CA210985NCI NIH HHS U24 CA210985NCI NIH HHS U54 CA143803NCI NIH HHS U54CA143803, CA163124, CA093900, CA143055NCI NIH HHS U54 CA163124New York Stem Cell Foundation Robertson Investigator
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) accounts for over 400,000 new cases and 175,000 deaths annually. Diagnostic RCC biomarkers may prevent overtreatment in patients with early disease. Extracellular vesicles (EVs) are a promising source of RCC biomarkers because EVs carry proteins and messenger RNA (mRNA) among other biomolecules. We aimed to identify biomarkers and assess biological functions of EV cargo from clear cell RCC (ccRCC), papillary RCC (pRCC), and benign kidney cell lines. EVs were enriched from conditioned cell media by size exclusion chromatography. The EV proteome was assessed using Tandem Mass Tag mass spectrometry (TMT-MS) and NanoString nCounter technology was used to profile 770 cancer-related mRNA present in EVs. The heterogeneity of protein and mRNA abundance and identification highlighted the heterogeneity of EV cargo, even between cell lines of a similar pathological group (e.g., ccRCC or pRCC). Overall, 1726 proteins were quantified across all EV samples, including 181 proteins that were detected in all samples. In the targeted profiling of mRNA by NanoString, 461 mRNAs were detected in EVs from at least one cell line, including 159 that were present in EVs from all cell lines. In addition to a shared EV cargo signature, pRCC, ccRCC, and/or benign renal cell lines also showed unique signatures. Using this multi-omics approach, we identified 34 protein candidate pRCC EV biomarkers and 20 protein and 8 mRNA candidate ccRCC EV biomarkers for clinical validation.

Indexed as

TranscriptomeApoptosisBiomarkers, TumorCarcinoma, PapillaryCarcinoma, Renal CellCell ProliferationDiagnosis, DifferentialExtracellular VesiclesGene Expression Regulation, NeoplasticHumansIn Vitro TechniquesKidneyKidney NeoplasmsProteomeRNA, MessengerTumor Cells, CulturedBiomarkers, TumorProteomeRNA, MessengerBiomarkersEV cargoExtracellular vesiclesKidney cancerMulti-omics

Identifiers

PMID34331598
PMCPMC8325656
OpenAlexW3185318169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.